Vnitr Lek 2024, 70(8):517-521 | DOI: 10.36290/vnl.2024.102

Kidney transplantation in patients with multiple myeloma: current options

Silvie Rajnochová Bloudíčková, Anna Novotná
Klinika nefrologie TC IKEM, Praha

Kidney disease is common in patients with multiple myeloma. Due to an unfavourable prognosis, patients with end-stage kidney disease in multiple myeloma were not accepted for kidney transplantation. Current therapeutic options for multiple myeloma have significantly improved the survival of these patients, thus more individuals are being referred for kidney transplantation. Recently published data support that a certain cohort of patients may benefit from transplantation. These are mainly patients with stable remission of multiple myeloma, whose treatment included stem cell transplantation. A multidisciplinary approach with an individualised assessment of transplantability is necessary. This review summarises recent knowledge regarding the possibility of kidney transplantation in patients with multiple myeloma.

Keywords: criteria, end-stage kidney disease, kidney transplantation, multiple myeloma, renal failure.

Accepted: November 29, 2024; Published: December 18, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rajnochová Bloudíčková S, Novotná A. Kidney transplantation in patients with multiple myeloma: current options. Vnitr Lek. 2024;70(8):517-521. doi: 10.36290/vnl.2024.102.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. https://www.hematology.cz/cervena-kniha-lecebne-postupy-v-hematologii/
    2. Malúšková D, Svobodová I, Kučerová M, et al. Epidemiology of multiple myeloma in the Czech Republic. Klin. Onkol. 2017;30:35-42. Go to original source... Go to PubMed...
    3. Barlogie B, Mitchell A, van Rhee F, et al. Curing myeloma at last: defining criteria and providing the evidence. Blood 2014;124:3043-3051. doi: 10.1182/blood-2014-07-552059 Go to original source... Go to PubMed...
    4. Hájek R, Maisnar V, Krejčî M, et al. Diagnostika a léčba mnohočetného myelomu. Transf. Hematol. Dnes. 2018;(Supl.1):1-155.
    5. Rajkumar SV. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2014;89:998-1009. doi: 10.1002/ajh.23810. Go to original source... Go to PubMed...
    6. https://www.myeloma.cz/res/file/guidelines/2023-transfuze-hematologie-dnes.pdf
    7. Rhee F, van, Szymonifka J, Anaissie E, et al. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood.2010;116:1220-1227. doi: 10.1182/blood-2010-01-264333. Go to original source... Go to PubMed...
    8. Heher EC, Rennke HG, Laubach JP, et al. Kidney disease and multiple myeloma. Clin J Am Soc Nephrol. 2013;8:2007-2017. doi: 10.2215/CJN.12231212. Go to original source... Go to PubMed...
    9. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21-33. doi: 10.4065/78. 1. 21. Go to original source...
    10. Klomjit N, Leung N, Fervenza F, et al. Rate and predictors of finding monoclonal gammopathy of renal significance (MGRS) lesions on kidney biopsy in patients with monoclonal gammopathy. J Am Soc Nephrol. 2020;31:2400-2411. doi: 10.1681/ASN.2020010054. Go to original source... Go to PubMed...
    11. Dykes K, Desale S, Javaid B, Miatlovich K, Kessler C. A New Reality for Multiple Myeloma Renal Failure: US Data Report on Kidney Transplant Outcomes. Clin Lymphoma Myeloma Leuk. 2022 May;22(5):e314-e320. doi: 10.1016/j.clml.2021. 11. 002. Go to original source...
    12. Bridoux F, Carron PL, Pegourie B, et al. for the MYRE Study Group. Effect of high-cutoff hemodialysis vs. conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical trial. JAMA 2017;318: 2099-2110. doi: 10.1001/jama.2017.17924. Go to original source... Go to PubMed...
    13. Hutchison CA, Cockwell P, Moroz V, et al. High cut off versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib- based chemotherapy (EuLITE): a phase 2 randomised controlled trial. Lancet Haematol. 2019;6: e217-e228. doi: 10.1016/S2352-3026(19)30014-6. Go to original source... Go to PubMed...
    14. Au EH, Chapman JR, Craig JC, et al. Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant. J Am Soc Nephrol. 2019;30(3):471-480. doi: 10.1681/ASN.2018090906. Go to original source... Go to PubMed...
    15. Decourt A, Gondouin B, Delaroziere JC, et al. Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis. Clin J Am Soc Nephrol. 2016 Mar 7;11(3):431-441. doi: 10.2215/CJN.06290615. Go to original source... Go to PubMed...
    16. Huskey JL, Heilman RL, Khamash H, et al. Kidney transplant in the era of modern therapy for multiple myeloma. Transplantation. 2018;102:1994-2001. doi: 10.1097/TP.0000000000002449. Go to original source... Go to PubMed...
    17. Chitty DW, Hartley-Brown MA, Abate M, et al. Kidney transplantation in patients with multiple myeloma: narrative analysis and review of the last two decades. Nephrol Dial Transplant. 2022 Aug 22;37(9):1616-1626. doi: 10.1093/ndt/gfaa361. Go to original source... Go to PubMed...
    18. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int. 1996 Jul;50(1):235-42. doi: 10.1038/ki.1996.307. Go to original source... Go to PubMed...
    19. Tsakiris DJ, Stel VS, Finne P, et al. Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study. Nephrol Dial Transplant. 2010;25(4):1200-1206. doi: 10.1093/ndt/gfp679. Go to original source... Go to PubMed...
    20. Campistol JM, Cuervas-Mons V, Manito N, et al. New concepts and best practices for management of pre- and post-transplantation cancer. Transplant Rev (Orlando). 2012 Oct;26(4):261-79. doi: 10.1016/j.trre.2012. 07. 001. Go to original source...
    21. Albugami M, Kiberd B. Malignancies: pre and post transplantation strategies. Transplant Rev. 2014,28:76-83. doi: 10.1016/j.trre.2013. 12. 002. Go to original source...
    22. Jakubov K, Kment M, Viklický O. Mnohočetný myelom jako přîčina primárnî afunkce štěpu po transplantaci ledviny. VnitřLék. 2024;70(4):241-244. doi.org/10.36290/vnl.2024.047. Go to original source...
    23. KDIGO, https://kdigo.org/wp-content/uploads/2018/08/KDIGO-Txp-Candidate-GL-FINAL.pdf.
    24. Fernandez-Caballero M, Salmeron D, Chirlaque MD, et al. Increasing therapy-related myeloid neoplasms in multiple myeloma. Eur J Clin Invest. 2018; 49: e13050. doi: 10.1111/eci.13050. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.